

Special Issue

The Evolving Landscape of Treatment against Unresectable Malignant Pleural Mesothelioma (MPM): Novel Options and Future Outlook

Message from the Guest Editors

After a long period of nihilism and a lack of additional therapeutic options beyond pemetrexed and platinum, recent years have witnessed extraordinary progress in the research landscape of malignant pleural mesothelioma (MPM), leading to a rapidly evolving therapeutic scenario. As in other cancers, immunotherapy with immune checkpoint inhibitors has represented a turning point in the therapeutic algorithm of unresectable MPM, with the combination of nivolumab and ipilimumab showing a significant survival benefit over standard chemotherapy in the first-line setting. However, there is increasing evidence that only a subset of patients can achieve the highest benefit, depending on specific cellular features of the tumor microenvironment. Therefore, stratified approaches to immunotherapy, including co-inhibition of checkpoint receptors and combinations with chemotherapy or other agents, are needed to improve clinical outcomes further. For this Special Issue, we welcome original and review papers that deal with novel therapeutic options in unresectable MPM.

Guest Editors

Dr. Maurizio D'Incalci

Laboratory of Cancer Pharmacology, Humanitas Research Hospital, Humanitas University, 20072 Pieve Emanuele (MI), Italy

Dr. Giovanni Luca Ceresoli

Department of Oncology, Thoracic and Urologic Oncology Unit, Cliniche Humanitas Gavazzeni, via Gavazzeni 21, 24125 Bergamo, Italy

Deadline for manuscript submissions

closed (1 June 2023)



Cancers

an Open Access Journal
by MDPI

Impact Factor 4.4
CiteScore 8.8
Indexed in PubMed



mdpi.com/si/100650

Cancers
Editorial Office
MDPI, Grosspeteranlage 5
4052 Basel, Switzerland
Tel: +41 61 683 77 34
cancers@mdpi.com

[mdpi.com/journal/
cancers](https://mdpi.com/journal/cancers)





Cancers

an Open Access Journal
by MDPI

Impact Factor 4.4
CiteScore 8.8
Indexed in PubMed



[mdpi.com/journal/
cancers](https://mdpi.com/journal/cancers)



About the Journal

Message from the Editor-in-Chief

Cancers is an international online journal addressing both clinical and basic science issues related to cancer research. The journal is publishing in Open Access format, which will certainly evolve to ensure that the journal takes full advantage of the rapidly changing world of information and knowledge dissemination. It publishes high-quality clinical, translational, and basic science research on cancer prevention, initiation, progression, and treatment, as well as other related topics, particularly to capture the most seminal studies in the rapidly growing area of immunology, immunotherapy, and tumor microenvironment.

Editor-in-Chief

Prof. Dr. Samuel C. Mok

Department of Gynecologic Oncology and Reproductive Medicine, The University of Texas MD Anderson Cancer Center, Houston, TX 77030, USA

Author Benefits

Open Access:

free for readers, with article processing charges (APC) paid by authors or their institutions.

High Visibility:

indexed within Scopus, SCIE (Web of Science), PubMed, PMC, Embase, CAPlus / SciFinder, and other databases.

Journal Rank:

JCR - Q2 (Oncology) / CiteScore - Q1 (Oncology)